[Business Wire] – Alexion Pharmaceuticals, Inc. today announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab in patients with refractory generalized myasthenia gravis . Read more on this. Alexion Pharmaceuticals, Inc. (ALXN) , currently valued at $34.72B, opened this morning at $154.02. Today’s price range has been between $152.14 and $155.78 per share with its 52-week range being $124.16 to $208.88. Priced at 30.24x this year’s forecasted earnings, ALXN shares are relatively expensive compared to the industry’s -0.21x forward p/e ratio. Consensus earnings for the current quarter by the 20 sell-side analysts covering the stock is an estimate of $1.18 per share, which would be $0.26 worse than the year-ago quarter and a $0.06 sequential decrease. Investors should also note that the full-year EPS estimate of $5.05 is a $0.06 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $742.68 Million. If realized, that would be a 16.74% increase over the year-ago quarter. Recently, Robert W. Baird downgraded ALXN from Outperform to Neutral (Mar 8, 2016). Previously, Citigroup Initiated ALXN at to Buy. When considering if perhaps the stock is under or overvalued, the average price target is $194.61, which is 26.35% above where the stock opened this morning. See more in (NASDAQ:ALXN) Similar Articles: Market Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report First Quarter 2016 Results on Thursday, April 28, 2016 Market Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) to Ring The Nasdaq Stock Market Opening Bell Stock Update: Alexion Pharmaceuticals Inc (NASDAQ:ALXN) – Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Results on Wednesday, February 3, 2016